Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Renal Insufficiency: later-stage trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Chronic Renal Insufficiency: 4 US clinical trials tracked, none currently recruiting.
Chronic Renal Insufficiency is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Genzyme, a Sanofi Company, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-renal-insufficiency
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Chronic Renal Insufficiency has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Renal Insufficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Renal Insufficiency is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC
University of Pennsylvania
NCT02685995
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Albert Einstein College of Medicine
NCT01029002
Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
VA Office of Research and Development
NCT01574157
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
Genzyme, a Sanofi Company
NCT00123461
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Renal Insufficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Renal Insufficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Renal Insufficiency page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Chronic Renal Insufficiency trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Genzyme, a Sanofi Company sponsors the most Chronic Renal Insufficiency trials on record, review their full trial history before evaluating a specific study. See Genzyme, a Sanofi Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Renal Insufficiency condition card totals 4 registered trials; most-linked intervention Palindrome TDC; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.